News

Post-operative myasthenic crisis is a dangerous complication after thymus removal surgery for people with myasthenia gravis (MG) who had no tumor in their thymus, according to researchers who set out to identify factors that increase this risk in a recent study. They determined risk factors to be: having a…

Early and aggressive treatments tend to lead to better control of myasthenia gravis (MG) symptoms, a recent study reports. The study suggests MG patients given early treatment with high doses of the corticosteroid methylprednisolone directly into the bloodstream are more likely to have minimal disease manifestations. “The data presented…

Being male, requiring intubation, and receiving plasma exchange therapy were identified as the main predictors of longer hospital stays following an acute episode of disease worsening in people with myasthenia gravis (MG), according to a recent study. Data also show that patients who underwent surgery to remove the…

Sanofi is stopping the clinical development of tolebrutinib for treating myasthenia gravis (MG), the company announced in a recent press release. The decision was made after “careful evaluation of the emerging competitive treatment landscape in MG,” according to Sanofi, and will result in discontinuing the Phase…

Patient dosing has begun in the first placebo-controlled clinical trial evaluating Cartesian Therapeutics’ Descartes-08, an investigational CAR T-cell therapy for people with generalized myasthenia gravis (gMG). The Phase 2b randomized controlled trial (RCT), to include up to 30 adults with gMG, follows a crossover design, in which participants…

The Myasthenia Gravis Foundation of America (MGFA) has partnered with Alira Health to relaunch a patient registry for people with myasthenia gravis (MG) that “capitalizes on technological advances,” the nonprofit announced. The initial registry was launched in 2013. The rebranded MGFA Global MG Patient Registry is…

MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed. The findings, some of which were reported previously at a scientific conference, supported Cabaletta Bio’s request for a…

Treatment with an antibody targeting the interleukin-23 (IL-23) protein reduced symptoms and eased inflammation in mouse models of myasthenia gravis (MG), a study found. Evidence suggested the antibody lowers the activation of T-helper 17 (Th17) cells — a cell family implicated in MG and other autoimmune diseases — in…

Ultomiris (ravulizumab-cwvz) has been approved in Canada to treat adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR), the most common type of MG-causing antibody. The announcement came less than a year after Ultomiris was approved for the condition in the U.S., and…

Researchers have identified clinical factors that increase the risk of a post-operative myasthenic crisis (POMC) for patients with myasthenia gravis (MG) who have surgery to remove the thymus gland. Among the risk factors listed are more severe MG with respiratory muscle involvement, pre-operative use of a high dose of pyridostigmine…